OrientBio Advances Toxicity and Efficacy Prediction with Non-clinical Primate Data

Bio infrastructure specialist OrientBio is advancing the sophistication of toxicity and efficacy prediction by utilizing non-clinical primate data.

On July 22, OrientBio announced that it will expand its “Non-clinical Data AI Assetization” initiative, which systematically accumulates pathology, hematology, imaging, toxicity, and efficacy evaluation data generated during research-use primate non-clinical studies and builds them into an artificial intelligence (AI) database (DB).

Non-clinical Data AI Assetization is a CRO (contract research organization) business model that uses AI to analyze accumulated data, precisely predict the toxicity and efficacy of new drug candidates, and reduce both the time and cost required for drug development through a data-driven approach.

OrientBio, through a contract with its affiliate Orient Cam for exclusive rights to primate non-clinical testing, has established a business system that connects supply, test execution, quality assurance (QA), and data analysis. By standardizing non-clinical data as AI assets, OrientBio aims to support the analysis of new drug candidates and R&D decision-making, as well as to collaborate with related companies and research institutions to expand into a global AI research support service.

An OrientBio official stated, “The AI bio platform business is a new growth engine that converts accumulated non-clinical data into high value-added research assets,” adding, “We will further enhance our business structure, expand collaboration with global bio companies, and do our utmost to improve both corporate and shareholder value.”

This content was produced with the assistance of AI translation services.